Key Points
- CRISPR Therapeutics director Ali Behbahani sold 13,679 shares for approximately $780,934 at an average price of $57.09, reducing his ownership by 45.12% to 16,637 shares.
- CRSP shares opened at $58.33, with a one-year trading range of $44.12 to $78.48 and a market capitalization of about $5.64 billion. The company reported a quarterly loss of $0.94 per share on $10.18 million in revenue.
- Analysts have a “Moderate Buy” consensus with an average price target of $67.94, while institutional investors and hedge funds own approximately 69.2% of the stock.
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) Director Ali Behbahani sold 13,679 shares of CRISPR Therapeutics stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $57.09, for a total value of $780,934.11. Following the completion of the transaction, the director owned 16,637 shares in the company, valued at $949,806.33. This trade represents a 45.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
CRISPR Therapeutics Stock Performance
CRSP stock opened at $58.33 on Tuesday. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $78.48. The firm has a market cap of $5.64 billion, a price-to-earnings ratio of -12.25 and a beta of 1.76. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The firm has a 50-day simple moving average of $53.23 and a two-hundred day simple moving average of $52.78.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The firm had revenue of $10.18 million during the quarter. On average, equities analysts forecast that CRISPR Therapeutics AG will post -4.47 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
CRSP has been the subject of several analyst reports. Morgan Stanley set a $60.00 price objective on CRISPR Therapeutics and gave the company an "equal weight" rating in a report on Thursday, June 11th. Citigroup restated a "market outperform" rating on shares of CRISPR Therapeutics in a research note on Tuesday, August 25th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Wall Street Zen raised CRISPR Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $67.94.
Check Out Our Latest Stock Analysis on CRSP
Hedge Funds Weigh In On CRISPR Therapeutics
Several hedge funds have recently made changes to their positions in the company. Capital International Investors lifted its holdings in shares of CRISPR Therapeutics by 4.3% during the fourth quarter. Capital International Investors now owns 5,892,745 shares of the company's stock worth $309,016,000 after purchasing an additional 243,487 shares during the period. Geode Capital Management LLC increased its holdings in CRISPR Therapeutics by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 2,249,223 shares of the company's stock worth $117,971,000 after buying an additional 108,053 shares during the period. Norges Bank purchased a new position in CRISPR Therapeutics during the 4th quarter worth approximately $25,706,000. Swiss National Bank lifted its stake in CRISPR Therapeutics by 5.1% during the 1st quarter. Swiss National Bank now owns 169,700 shares of the company's stock valued at $8,073,000 after acquiring an additional 8,200 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new stake in CRISPR Therapeutics during the 1st quarter valued at approximately $7,136,000. 69.20% of the stock is owned by institutional investors and hedge funds.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company's programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.
Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient's blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
